Naproxen and Cromolyn as New Glycogen Synthase Kinase 3β Inhibitors for Amelioration of Diabetes and Obesity: An Investigation by Docking Simulation and Subsequent In Vitro/In Vivo Biochemical Evaluation

@article{Motawi2013NaproxenAC,
  title={Naproxen and Cromolyn as New Glycogen Synthase Kinase 3$\beta$ Inhibitors for Amelioration of Diabetes and Obesity: An Investigation by Docking Simulation and Subsequent In Vitro/In Vivo Biochemical Evaluation},
  author={Tarek Mohamed Kamal Motawi and Yasser K. Bustanji and Shohda A. El-Maraghy and Mutasem Omar Taha and Mohamed A Al Ghussein},
  journal={Journal of Biochemical and Molecular Toxicology},
  year={2013},
  volume={27}
}
Naproxen and cromolyn were investigated as new inhibitors of glycogen synthase kinase‐3β (GSK‐3β) in an attempt to explain their hypoglycemic properties. Study included simulated docking experiments, in vitro enzyme inhibition assay, and in vivo validations. Both drugs not only were optimally fitted within a GSK‐3β binding pocket via several attractive interactions with key amino acids but also exhibited potent in vitro enzymatic inhibitory activities of IC50 1.5 and 2.0 µM for naproxen and… 
Inhibition of GSK-3β restores delayed gastric emptying in obesity-induced diabetic female mice.
TLDR
Findings emphasize the importance of GSK-3β on regulating gastric Nrf2 and nitrergic mediated gastric emptying in obese/diabetic rodents.
Spleen-kidney supplementing formula alleviates insulin resistance via regulating AKT/glycogen synthase kinase 3β pathway in rats with type 2 diabetic induced by high-fat diet.
TLDR
Spleen-kidney supplementing formula significantly relieved the symptoms of polydipsia, polyuria and weight loss in type 2 diabetic rats, reduced FBG and HbA1c levels, increased glycogen content, and improved insulin sensitivity.
Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases
TLDR
The specific roles of GSK3 in energy metabolism regulation in tissues that are tightly associated with energy metabolism and the functions of G SK3 in the development of metabolic disorders are summarized.
ATIC as a link between antirheumatic drugs and regulation of energy metabolism in skeletal muscle
TLDR
This work reviews antirheumatic drugs that inhibit ATIC, the final enzyme in the de novo purine biosynthesis, responsible for conversion of ZMP to IMP and discusses whether these drugs might improve systemic glucose homeostasis by inhibiting ATIC and activating AMPK in skeletal muscle.
Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging
TLDR
The structure, function, expression levels, and ligand-binding properties of GSK-3 and its connection to various diseases are reviewed and a rational perspective and possible route to selective and effective G SKS-3 inhibitors is discussed.
Potential Effects of Nonsteroidal Anti-Inflammatory Drugs in the Prevention and Treatment of Type 2 Diabetes Mellitus
TLDR
The scientific literature of the last 5 years regarding the potential effects of NSAID treatment on diabetes prevention/treatment is overviewed and papers that suggest new areas for further investigation are included.
Modulating effect of cromolyn on Akt, MAPK, ERK and DNMT expression pattern in 7,12-dimethylbenz (a) anthracene induced hamster buccal pouch carcinogenesis
TLDR
The antitumor potential of cromolyn might be partly due to its modulating effect on the expression pattern of above mentioned cancer related biomarkers.
ANTI-INFLAMMATORY AND ANTI-ANGIOGENIC POTENTIAL OF CROMOLYN IN 7, 12-DIMETHYLBENZ(A)ANTHRACENE INDUCED HAMSTER BUCCAL POUCH CARCINOGENESIS
TLDR
The tumor preventive potential of cromolyn relies on its anti-inflammatory and anti-angiogenic potential in 7, 12-dimethylbenz(a)anthracene induced hamster buccal pouch carcinogenesis.
ANTI-INFLAMMATORY AND ANTI-ANGIOGENIC POTENTIAL OF CROMOLYN IN 7, 12- DIMETHYLBENZ (A) ANTHRACENE INDUCED HAMSTER BUCCAL POUCH CARCINOGENESIS Original Article
TLDR
The tumor preventive potential of cromolyn relies on its anti-inflammatory and anti-angiogenic potential in 7, 12-dimethylbenz(a)anthracene induced hamster buccal pouch carcinogenesis.
Chronic over-nutrition and dysregulation of GSK3 in diseases
TLDR
Current understanding on environmental and nutritional factors contributing to GSK3 regulation (or dysregulation) through the PI3K/PDK1/Akt/GSK3 axis is summarized, and the newly discovered role that PLIN2 plays in regulating G SK3 activity and GSK2 downstream pathways is highlighted.
...
...

References

SHOWING 1-10 OF 39 REFERENCES
Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation
TLDR
In vivo experiments illustrated that curcumin significantly increases liver glycogen in fasting Balb/c mice and strongly suggest that the diverse pharmacological activities ofCurcumin are at least partially mediated by inhibition of GSK-3β.
First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
TLDR
The synthesis, biological evaluation, and SAR of the small heterocyclic thiadiazolidinones (TDZD) are described as the first non-ATP competitive inhibitor of GSK-3beta, based on the reactivity of sulfenyl chlorides.
Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle.
TLDR
Results indicate that selective GSK3 inhibition enhances insulin action in insulin-resistant skeletal muscle of the prediabetic obese Zucker rat, at least in part by relieving the deleterious effects of G SK3 action on post-IR insulin signaling.
Naproxen-PC: A GI safe and highly effective anti-inflammatory
TLDR
Naproxen-PC appears to induce significantly less GI injury and bleeding in two rodent model systems while maintaining anti-inflammatory and COX-inhibitory activity.
Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes.
TLDR
It is concluded that increased GSK-3 expression in diabetic muscle may contribute to the impaired GS activity and skeletal muscle insulin resistance present in type 2 diabetes.
Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418*
TLDR
AR-A014418 is the first compound of a family of specific inhibitors of GSK3 that does not significantly inhibit closely related kinases such as cdk2 or cdk5 and may have important applications as a tool to elucidate the role of Gsk3 in cellular signaling and possibly in Alzheimer's disease.
Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes.
TLDR
GSK3 is focused on as a central negative regulator in the insulin signaling pathway, its role in insulin resistance, and the utility of GSK3 inhibitors for intervention and control of metabolic diseases including type 2 diabetes.
Renal and hepatic transporter expression in type 2 diabetic rats.
TLDR
Research in type 2 diabetic rats investigated alterations in the renal and hepatic expression of organic anion and cation transporters, multidrug resistance-associated proteins (Mrps), breast cancer resistance protein (Bcrp), P-glycoprotein (Pgp), and hepatatic Na(+)-taurocholate cotransporting polypeptide (Ntcp) in type 1 diabetic rats to investigate changes in chemical disposition and drug pharmacokinetics.
...
...